Jasper Therapeutics
JSPR
42 hedge funds and large institutions have $79.2M invested in Jasper Therapeutics in 2020 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
180% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 5
27% more funds holding
Funds holding: 33 → 42 (+9)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
11% more capital invested
Capital invested by funds: $71.2M → $79.2M (+$7.99M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCL
Glazer Capital LLC
New York
|
+$5.62M |
| 2 |
Goldman Sachs
New York
|
+$5.19M |
| 3 |
PSAMP
P. Schoenfeld Asset Management (PSAM)
New York
|
+$4.75M |
| 4 |
RCM
Rivernorth Capital Management
West Palm Beach,
Florida
|
+$1.93M |
| 5 |
BCM
Beryl Capital Management
Redondo Beach,
California
|
+$1.62M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCAM
Owl Creek Asset Management
New York
|
-$8.82M |
| 2 |
AA
AQR Arbitrage
Greenwich,
Connecticut
|
-$2.31M |
| 3 |
LIM
Longfellow Investment Management
Boston,
Massachusetts
|
-$1.93M |
| 4 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.79M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$1.14M |
JSPR Hedge Fund Activity: Q3 2020 in Review
42 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q3 2020, worth a combined $79.2M — up 11% from $71.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new JSPR positions and 5 closed out — a net gain of 9 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Glazer Capital LLC, adding an estimated $5.62M. The largest seller was Owl Creek Asset Management, exiting entirely with an estimated $8.82M sold.
- 42 institutional investors held Jasper Therapeutics (JSPR) as of Q3 2020, up from 33 in Q2 2020.
- Funds reported $79.2M of Jasper Therapeutics stock for Q3 2020, up 11% quarter-over-quarter.
- 14 funds opened new Jasper Therapeutics positions in Q3 2020 and 5 closed out, a net change of +9 holders.
- The largest Jasper Therapeutics buyer in Q3 2020 was Glazer Capital LLC, an estimated $5.62M added.
- The largest Jasper Therapeutics seller in Q3 2020 was Owl Creek Asset Management, an estimated $8.82M sold.
Based on aggregated 13F filings for Q3 2020.